genflow biosciences
longer better life

CORPORATE
OVERVIEW

May 2025

LSE: **GENF** - OTCQB: **GENFF**

FORWARD LOOKING STATEMENTS

This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts.

Certain information and statements include financial projections that are based upon certain assumptions and assessments made by Genflow Biosciences' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the Genflow Biosciences' management believes that the forward-looking statements and information are reasonable, the Genflow Biosciences' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of Genflow Biosciences. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by Genflow Biosciences with the AMF. Such forward-looking statements are not guarantees of future performance.

This presentation includes only summary information and should be read with the Genflow Biosciences Universal Registration Document filed with the AMF on 15 April 2022 including the 2021 Financial results, all available on the Genflow Biosciences' website. Other than as required by applicable law, Genflow Biosciences issues this presentation at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of the Shares to any person in any jurisdiction where such an offer or solicitation is not permitted. The Shares may not be offered or sold, directly or indirectly, may be distributed or sent to any person or into any jurisdiction, except in circumstances that will result in the compliance with all applicable laws and regulations.

Persons into whose possession this presentation may come are required to inform themselves about, and to observe all, such restrictions. The Company accept no responsibility for any violation by any person, whether or not it is a prospective purchaser of Shares, of any such restriction. The information contained in this presentation has not been independently verified and no commitment, representation or warranty, express or implied, is given by the Company or anyone of its directors, officers or respective affiliates or any other person and may not serve as the basis for the veracity, completeness, accuracy or completeness of the information contained in this document (or for any omission of any information in this presentation) or any other information relating to the Company or its affiliates.

The information contained in this document is provided only as of the date of this document and may be subject to update, supplement, revision, verification and modification. They can be modified significantly. The Company is not subject to an obligation to update the information contained in this document and any opinion expressed in this document is subject to change without notice. The Company, its advisers, its representatives cannot be held responsible in any manner whatsoever for any loss of any nature whatsoever resulting from the use of this document or its contents or otherwise related in any way to this document.

This document contains information relating to the Company's markets and the positioning of the Company in these markets. This information is derived from various sources and estimates of the Company. Investors cannot rely on this information to make their investment decision.

WHO WE ARE

Pioneering Novel Gene Therapeutics for a Longer, Healthier Life

MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs

CENTENARIAN SIRT6 (cent SIRT6) GENE: patented variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases

PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH

SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech

ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Sarcopenia, Werner and life extension of dogs

LSE: **GENF** - OTCQB: **GENFF**

SCIENTIFIC ADVISORY BOARD

DR. VERA GORBUNOVA, PHD

CO Director

Rochester Aging Research Center

Affiliated With

Weizmann Institute Of Science



DR. ERIC VERDIN MD/PHD

CEO & President

Buck Institute

Affiliated With

UCSF School Of Medicine

Affiliated with

DR. MATTHEW HIRSCHEY, PHD

Assistant Professor

Duke University School of Medicine

Affiliated With

American Heart Association

Affiliated with

DR. MANLIO VINCIGUERRA, PHD

Principle Investigator

University of Liverpool

Affiliated With

UCL

Affiliated with

PROF. DR. SVEN FRANCQUE, PHD

NASH Expert

University of Antwerp

DR. MARY RINELLA, MD

NASH Expert

University of Chicago Medicine

LSE: **GENF** - OTCQB: **GENFF**

MANAGEMENT

TAMARA JOSEPH

Chairperson

- Seasoned healthcare leader with extensive experience in both early-stage and commercial biotech companies
- Supported Nasdaq financings of over $800m
- Currently serving as Chief Legal Officer at Spero Therapeutics Inc. (NASDAQ:SPRO)
- Served as an adviser to the boards of five US publicly traded biotechs, including Cubist Pharmaceuticals Inc.
- BA in Economics from Duke, a JD from the University of Michigan, and LLM degrees from Belgium and the University of Paris



DR ERIC LEIRE MD MBA

Founder & CEO

- MD and MBA, Eric has been involved in biotech for over 30 years
- Research position at Harvard University. Held senior positions including CEO of publicly traded biotech companies (Nasdaq, OTC.QB, OMX.Nasdaq)
- Inventor of several patents and author of medical peer-reviewed publications

DEVELOPMENT PIPELINE

GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6 (cent SIRT6) in liver

Phase I/II MASH

IND-Enabling Phase

18 months to first-in-human PoC in 36 patients

GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6 (cent SIRT6) in fibroblasts

Werner Syndrome

36 months to first-in-human

GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6

Sarcopenia

Pre-clinical

GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases

Anti-aging for dogs

w/ Vet Partner

GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma

Ophthalmology

w/ Partner

COLLABORATIONS

UNIVERSITY OF ROCHESTER · CER Groupe · LIVERPOOL JOHN MOORES UNIVERSITY · ivexLab · exothera · Physiogenex

UNIVERSITY OF ROCHESTER · CER Groupe · EXO Biologics · ivexLab · EXOGENUS · RevaTis · ucb · LIVERPOOL JOHN MOORES UNIVERSITY

UNIVERSITY OF ROCHESTER · Syngene · UNIVERSITY OF LIVERPOOL · exothera · CER Groupe

LSE: **GENF** - OTCQB: **GENFF**

2024 & 2025 KEY HIGHLIGHTS

LARGE AND EXPANDING MARKET OPPORTUNITY

MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication

Awarded to new grants in 2024 expanding research pipeline

GROWING IP PORTFOLIO WITH LONG LIFE

2 patent families **SIRT6** centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)

MULTIPLE PROPRIETARY GENE DELIVERY SYSTEMS

Proprietary innovative gene delivery systems: AAVs, LNPs, exosomes, delivering cent SIRT6 DNA or mRNA

GF-1002 and GF-1004

Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner



LSE: **GENF** - OTCQB: **GENFF**

NEW PARTNERSHIPS EXPANDING PIPELINE

OPHTHALMOLOGY PLATFORM

New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow's proprietary Centenarian SIRT6 (cent SIRT6).

Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye.

Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system.

LEVERAGING AI FOR GENOMICS

New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles.

Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes.

Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH.

THANK YOU

Contact

CEO, GENFLOW BIOSCIENCES
Dr. Eric Leire: +32 477 495 881

HARBOR ACCESS INVESTOR RELATIONS
Jonathan Paterson : +1 475 477 9401

GENFLOW BIOSCIENCES
SRL Biopark Gosselies
48 rue Auguste Piccard
6041 Gosselies, Belgium

GENFLOW BIOSCIENCES INC.
Harvard Square
18 Brattle Street, Suite 400
Cambridge, MA 02138, US

LSE: **GENF** - OTCQB: **GENFF**

LONGEVITY LANDSCAPE

genflow biosciences
longer better life

COMPANY	OVERVIEW	TECHNOLOGY	FOCUSED ON	LOCATION
UNITY BIOTECHNOLOGY	CLINICAL STAGE, PHASE II NASDAQ **(UBX)** MKT CAP **$785M**	Small Molecules Senolytic	Senescence	USA, San Francisco, CA
AGEX THERAPEUTICS	PRE-CLINICAL STAGE NYSE **(AGE)** MKT CAP **$25M**	Therapeutics that seek to address human aging	Stem cells	USA, Almeda, CA
verve THERAPEUTICS	CLINICAL STAGE, PHASE I NASDAQ **(VERV)** MKT CAP **$885M**	In Vivo LNP CRIPR Gene editing	Hypercholesterolemia	USA, Cambridge, MA
FREQUENCY THERAPEUTICS	PRE-CLINICAL STAGE NASDAQ **(FREQ)** MKT CAP **$16M**	Small Molecules to Activate progenitor calls for MS	Stem cell exhaustion	USA, Woburn, MA
life BIOSCIENCES	PRE-CLINICAL STAGE PRIVATE RAISED **$124M**	Epigenetic reprogramming	Mitochondrial dysfunction	USA, Boston, MA
biosplice	CLINICAL STAGE, PHASE III PRIVATE RAISED **$778M**	Alternative splicing modulation to develop medicines to treat ageing-related diseases	Osteoarthritis	USA, San Diego, CA
REJUVENATE BIO	CLINICAL STAGE, PHASE I PRIVATE RAISED **$26M**	Gene Therapy	Proteostatis	USA, San Carlos, CA

LSE: **GENF** - OTCQB: **GENFF**

MARKET

Aging Is One of Our Greatest Societal & Economical Challenges

Increasing life expectancy, decreasing healthspan, rising healthcare costs – all highlight the urgent need for age-related disease treatments

88 yrs*



12-13 yrs*

2 yrs*

LIFE EXPECTANCY

***expected LE in relation to male babies born in the UK in 2018**

Source: Morgan AE, Davies TJ, Mc Auley MT. The role of DNA methylation in ageing and cancer. Proc Nutr Soc. 2018 Nov;77(4):412-422. doi: 10.1017/S0029665118000150. Epub 2018 Apr 30. PMID: 29708096

COMPARATIVE TRIAL IN AGED DOGS

Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs

Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified

26 aged Beagles dogs (age>10 years):

Group 1 (n=6): untreated

Group 2 (n=18): treated with gene therapy IV administration of naked DNA once a month for 6 months (6 injections in total)

0ne year dose escalating with 3 cohorts

300 days for Group 2, cohort 1 (6 dogs)

330 days for Group 2, cohort 2 (6 dogs) •

360 days for Group 2, cohort 3 (6 dogs), and Group 1 (6 dogs).
Acclimatization/screening period: 30 days

Treatment period: 180 days Follow-up period: 90 days

Endpoints: Pan-mammalian methylation clock (Steve Horvath) and sarcopenia (including muscle biopsies)



NAKED DNA DELIVERY

Naked DNA in vivo delivery in small mammals like dogs holds several advantages:

- **Safety and Simplicity:** Naked DNA lacks viral components, reducing the risk of immune responses and integration-related mutagenesis, making it safer than viral vectors.
- **Cost-Effectiveness:** Unlike complex viral vector production, plasmid DNA is relatively easy and inexpensive to produce.
- **Transient Expression:** Naked DNA delivers transgenes without permanent integration, which is ideal for temporary therapeutic needs or preclinical research where long-term expression is unnecessary.

Intravenous (IV) Administration:

- **Systemic Distribution:** IV injection enables the DNA to circulate widely, reaching multiple tissues, though uptake by cells is generally low.
- **Lower Expression Levels:** The naked DNA is more rapidly cleared from the bloodstream than when using intra-muscular injections, resulting in need for the veterinary to repeat the iv injections.



GENE REGULATION IN AGING

Aging is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage

MANY GENES REGULATE AGING.
OUR FOCUS IS THE CENTENARIAN **SIRT6 (cent SIRT6) GENE**



Aging is driven by interlinked Hallmarks, all rooted in DNA damage. Targeting one individual factor is unlikely to be effective



LSE: **GENF** - OTCQB: **GENFF**

SIRT6: REPAIRING DNA

SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells

SIRT6 gene codes for SIRT6 protein

Stronger SIRT6: Longer lifespan

The Ability of SIRT6 to stimulate DSB repair corelates with maximum lifespan (MLS) in rodents

5 Amino Acids determine the differential activities of SIRT6



Source: Tian et al., 2019, Cell 177, 622–638 April 18, 2019

FOCUS ON CENTENARIAN SIRT6 (cent SIRT6)

SIRT6 centenarian variant (cent SIRT6) gene has more efficient DNA repair properties

HOMOLOGOUS
Recombination Repair

NON-HOMOLOGOUS End
Joining Repair

RELATIVE PARP1
Ribosilation







MASH PROGRAM

Affects est. 35 million people globally

- Increasing prevalence
- Leading cause of chronic liver disease and liver transplant

Significant unmet medical need

Clear regulatory accelerated development pathway. EMA and FDA guidelines accept:

- ✓ Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH
- ✓ Histological changes are achievable within a 12-18-month time-frame
- ✓ Placebo control
- ✓ Conditional fast-track approval



Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016 Dec;65(6):1245-1257.
Vlad Ratziu, Sven Francque, Arun Sanyal, Breakthroughs in therapies for NASH and remaining challenges, Journal of Hepatology, Volume 76, Issue 6, 2022

EXOSOME DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE

Genflow’s patent-pending technology has already been tested in several preclinical studies

Non-Integrating, No Risk of Insertional Oncogenesis

Non-Replicating, Safe Transient Expression

Reduced Potential for Immunogenicity

LSE: **GENF** - OTCQB: **GENFF**

ADVANTAGES: EXOSOME DELIVERY

Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV

NO IMMUNOGENICITY

Lack of Local Systemic Immunogenicity

TARGETED DELIVERY

Engineered Exosome To Direct to Specific Cell Types



POTENCY ADVANTAGE

Improved Transduction

Verses Free AAVs Rapid Uptake

Sustained

THERAPEUTIC WINDOW

Potency Improvement, Local Retention, Lack of Systemic Leakage

Hudry E, Martin C, Gandhi S, György B, Scheffer DI, Mu D, Merkel SF, Mingozzi F, Fitzpatrick Z, Dimant H, Masek M, Ragan T, Tan S, Brisson AR, Ramirez SH, Hyman BT, Maguire CA. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 2016 Apr;23(4):380-92. doi: 10.1038/gt.2016.11. Epub 2016 Feb 2. Erratum in: Gene Ther. 2016 Nov;23 (11):819. PMID: 26836117; PMCID: PMC4824662.

INTELLECTUAL PROPERTY

EFS ID	1-21069	43268050
Application Number	US 63/188,573	US 63/222,557
Title of Invention	Variants of SIRT6 for use in preventing and/or treating age-related diseases	Method of in vivo administration of the coding sequence of the SIRT6 gene via Adeno-Associated-Virus
First Named Inventor	Vera Gorbunova, Seluanov and Suh	Eric Leire
Receipt Date	May 14, 2021	July 16, 2021
Ownership	Worldwide Exclusive license from University Rochester New York / Columbia University / Albert Einstein College of medicine	Genflow Biosciences SRL